Industry payments and brand-name tyrosine kinase inhibitor use amid generic entry
Clin Trials
.
2024 Apr;21(2):257-259.
doi: 10.1177/17407745231207971.
Epub 2023 Oct 31.
Authors
Q Wilton Sun
1
,
Howard P Forman
2
3
4
,
Joseph S Ross
3
5
Affiliations
1
Yale School of Medicine, New Haven, CT, USA.
2
Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, CT, USA.
3
Department of Health Policy and Management, Yale School of Public Health, New Haven, CT, USA.
4
Yale School of Management, New Haven, CT, USA.
5
Section of General Internal Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.
PMID:
37904526
DOI:
10.1177/17407745231207971
No abstract available
Publication types
Letter
MeSH terms
Drug Industry
Drugs, Generic*
Humans
Tyrosine Kinase Inhibitors*
Substances
Tyrosine Kinase Inhibitors
Drugs, Generic